Form 4 for MIRM Mirum Pharmaceuticals, Inc.
Accepted 2026-09-03 18:52:58 ET · period of report 2026-09-01 · accession 0001614740-26-000013 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-09-03 18:52 | 2026-09-01 | MIRM | Peetz Christopher | CEO, Dir | M - OptEx | $2.94 | +30.0K | 224.4K | +15% | +$88.1K |
| DMT | 2026-09-03 18:52 | 2026-09-01 | MIRM | Peetz Christopher | CEO, Dir | S - Sale+OE | $98.68 | -30.0K | 194.4K | -13% | -$2.96M |
| DT | 2026-09-03 18:52 | 2026-09-01 | MIRM | Peetz Christopher | CEO, Dir | M - OptEx | $0.00 | -30.0K | 58.5K | -34% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-01 | M | A | 30,000 | $2.94 | 224,440 | D | — | — | (F1) Includes 131 shares of Common Stock that were acquired by the Reporting Person on May 10, 2026, pursuant to the Issuer's Employee Stock Purchase Plan. |
| 2 | Common | Common Stock | 2026-09-01 | S | D | 8,312 | $98.08 | 216,128 | D | — | — | (F2) Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 2, 2026. (F3) The weighted average sale price for the transaction reported was $98.08, and the range of prices were between $97.47 and $98.42. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 3 | Common | Common Stock | 2026-09-01 | S | D | 21,688 | $98.91 | 194,440 | D | — | — | (F2) Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 2, 2026. (F4) The weighted average sale price for the transaction reported was $98.91, and the range of prices were between $98.49 and $99.38. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 4 | Derivative | Employee Stock Option (right to buy) | 2026-09-01 | M | D | 30,000 | $0.00 | 58,487 | D | $2.94 · — to 2029-03-11 | 30,000 Common Stock | (F5) The stock option is fully vested. |